TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12464951
Drug: Intranasal amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal amphotericin B (20 mL of a 100 microg/mL solution twice daily)
Study: 22671949
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group (traditional didactic teaching and drug refusal skills)
Study: 20642555
Drug: Woohwangcheongsimwon suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Woohwangcheongsimwon suspension
Study: 15080766
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily for 4 days plus lumiracoxib 400 mg
Study: 15080766
Drug: Aluminium hydroxide/magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminium hydroxide/magnesium hydroxide antacid plus lumiracoxib 400 mg
Study: 15080766
Drug: Lumiracoxib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 400 mg alone
Study: 8074020
Drug: Molsidomine infusion
Normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine infusion
Study: 2552552
Drug: Fragmin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragmin administered subcutaneously twice daily (initial dose 100 U anti‐Xa/kg/12 h, adjusted based on anti‐Xa activity)
Study: 2552552
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin administered by continuous infusion (initial dose 240 UI/kg/12 h, adjusted based on APTT)
Study: 25719937
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide implant (FAI)
Study: 24356595
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy during the DCCT
Study: 21352112
Drug: OPUS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPUS treatment (assertive community treatment with family involvement and social skills training)
Study: 21352112
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (contact with a community mental health centre)
Study: 12375299
Drug: New antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antidepressant (dose escalation)
Study: 8665883
Drug: diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 75 mg
Study: 94225
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 5% lidocaine and 5% prilocaine
Study: 94225
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 5% lidocaine and 5% prilocaine used daily for 3-4 weeks
Study: 27423432
Drug: Quercetin (162
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (162 mg/d)
Study: 21804338
Drug: Laughter therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laughter therapy (60 min, twice a week for 2 weeks, total of 4 sessions)
Study: 19782873
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment (including hand therapy and ultrasound)
Study: 14964742
Drug: Targeted biologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted biologic therapies
Study: 10743698
Drug: L-arginine 3
Normalized name: Natrol Men's Health L-Arginine 3,000mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine 3 x 500 mg/day
Study: 2205997
Drug: Regional intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional intravenous block
Study: 30924165
Drug: Lenograstim at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenograstim at 10 μg/kg/day for at least 4 consecutive days (early collection group)
Study: 30924165
Drug: Lenograstim at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenograstim at 10 μg/kg/day for at least 4 consecutive days (late collection group)
Study: 25296654
Drug: DHEA capsule
DrugBank: Prasterone sulfate (DB05804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA capsule 75 mg/day for at least 12 weeks before egg collection
Study: 22725663
Drug: Curcumin 1000
Normalized name: Radiance Platinum Turmeric Curcumin 1000mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 1000 mg capsules once daily for 14 days
Study: 2210021
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion (2 U bolus injection; 111 mU/min for 2 hours)
Study: 28740204
Drug: Topically administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically administered autologous APOSEC (12.5 × 106 PBMCs)
Study: 28740204
Drug: Topically administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically administered autologous APOSEC (25 × 106 PBMCs)
Study: 28740204
Drug: Topically administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically administered APOSEC (both doses)
Study: 25670636
Drug: Rosuvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (40 mg on admission, followed by 20 mg/day)
Study: 25670636
Drug: Rosuvastatin and
Normalized name: rosuvastatin and ramipril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin and No statin treatment (control group)
Study: 21334753
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg (S80)
Study: 16749654
Drug: SIMVA 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIMVA 20 mg
Study: 14996777
Drug: Treatment guidelines
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment guidelines tailored for the elderly with care management
Study: 8988065
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg tramadol in extensive metabolizers
Study: 8988065
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg tramadol in poor metabolizers
Study: 6652642
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol 80 mg, twice daily for 5 days
Study: 6652642
Drug: Oral metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metoprolol 100 mg, twice daily for 5 days
Study: 6652642
Drug: Intravenous propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propranolol 10 mg
Study: 6652642
Drug: Intravenous metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoprolol 20 mg
Study: 30902820
Drug: BI 655064
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 655064 (120 mg weekly for 12 weeks)
Study: 27636757
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy in addition to conventional treatment
Study: 27636757
Drug: Only photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only photodynamic therapy
Study: 22994867
Drug: Psychoacoustic Advanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoacoustic Advanced Combination Encoder (PACE)
Study: 22994867
Drug: Advance Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advance Combination Encoder (ACE)
Study: 19888030
Drug: Control (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (weekly vaginal assessment for Bishop score)
Study: 17513664
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg hyperbaric bupivacaine
Study: 17513664
Drug: 6.0 mg
Normalized name: Dimethicone 6.0 mg in 30 mL TOPICAL CREAM [Clapiel Revital Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.0 mg hyperbaric bupivacaine
Study: 15159466
Drug: Mirtazapine 15
Normalized name: mirtazapine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 15 to 30 mg/day
Study: 27585447
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of daily living (control group)
Study: 23382519
Drug: High frequency
Normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL SOLUTION [enMotion Foam High Frequency Use]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High frequency (HF) SPG stimulation for treatment
Study: 15118469
Drug: Ahmed drainage
Normalized name: PLEURX DRAINAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ahmed drainage implant
Study: 1979522
Drug: Acyclovir (ACV)
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir (ACV) 50 mg/kg once a week in a 3-hour infusion with 1 g oral probenecid
Study: 27835050
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of Chromium Picolinate (600 mcg/day)
Study: 27835050
Drug: Insulin AUC
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin AUC (all groups)
Study: 27835050
Drug: Insulin Sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin Sensitivity Index (ISI) (all groups)
Study: 23864641
Drug: 5% CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% CO2 inhalation during LBNP
Study: 9305478
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 400 mg b.d. + clarithromycin 250 mg b.d. + metronidazole 500 mg b.d. (group A)
Study: 9305478
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 400 mg b.d. + clarithromycin 250 mg b.d. + metronidazole 250 mg q.d.s (group B)
Study: 3095522
Drug: High aluminum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High aluminum load from experimental high calcium- and phosphorus-containing PN solution (306 +/- 26 micrograms/L) for up to 6 weeks
Study: 3095522
Drug: Lower aluminum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower aluminum load from standard Ca-P solutions (144 +/- 16 micrograms/L)
Study: 29517580
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (topical prostaglandins)
Study: 29517580
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (topical beta blockers and carbonic anhydrase inhibitors)
Study: 29517580
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intraocular pressure-lowering medications)
Study: 22746337
Drug: Yohimbine 5
Normalized name: yohimbine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine 5 mg
Study: 15195048
Drug: Oral spray
Normalized name: Oral Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral spray lubricant applied before bedtime
Study: 8254783
Drug: Ciprofloxacin 100
Normalized name: ciprofloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 100 mg at night for 6 months
Study: 3303785
Drug: Conventional injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection therapy (CIT)
Study: 2178389
Drug: Acorns (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acorns (25 g carbohydrate portion)
Study: 2178389
Drug: Corn (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn (25 g carbohydrate portion)
Study: 26024575
Drug: Lycopene in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene in capsule
Study: 23121338
Drug: Hybrid therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid therapy: pantoprazole 40 mg/b.i.d. and amoxicillin 1 g/b.i.d. for 14 days plus 500 mg clarithromycin and 500 mg tinidazole, both twice daily for the last 7 days
Study: 23121338
Drug: Sequential therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy: 40 mg pantoprazole/b.i.d. for 10 days and 1 g amoxicillin/b.i.d. for the first 5 days, followed by 500 mg clarithromycin/b.i.d. and 500 mg tinidazole/b.i.d. for the last 5 days
Study: 19094067
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (4.8 pmol/kg per min)
Study: 17409891
Drug: Radiation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation plus chemotherapy
Study: 11160760
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of memantine
Study: 9283163
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no epidural morphine)
Study: 7509261
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of urtica/pygeum preparation (300 mg of Urtica dioica root extract combined with 25 mg of Pygeum africanum bark extract)
Study: 7509261
Drug: Half the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half the standard dose of urtica/pygeum preparation
Study: 3080461
Drug: Isocal supplemented
Normalized name: ISOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocal supplemented with NaCl to give 2 g Na/day (Diet B)
Study: 3080461
Drug: Unsupplemented Isocal
Normalized name: ISOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupplemented Isocal providing 1 g Na/day (Diet C)
Study: 3080461
Drug: Mixed foods
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed foods (3-6 g Na/day) orally before gastrostomy (Diet A)
Study: 21962092
Drug: Flunisolide HFA
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flunisolide HFA (2 puffs twice daily, 85 μg/puff)
Study: 16327016
Drug: ET(A)-receptor antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ET(A)-receptor antagonist (BQ-123)
Study: 31085788
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B liposomal gel
Study: 31085788
Drug: Paromomycin sulfate
Normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin sulfate liposomal gel
Study: 31085788
Drug: Daylight option
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daylight option of photodynamic therapy
Study: 16297052
Drug: Tacrolimus monotherapy
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus monotherapy (TACRO)
Study: 16297052
Drug: Tacrolimus plus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus plus steroids (TACRO + ST)
Study: 16297052
Drug: Tacrolimus monotherapy
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus monotherapy (real-TACRO)
Study: 16297052
Drug: Tacrolimus plus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus plus steroids (real-TACRO + ST)
Study: 9569054
Drug: FEP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEP regimen (epirubicin 35 mg/m², etoposide 120 mg/m², cisplatin 45 mg/m²)
Study: 9569054
Drug: FEP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEP regimen plus low-dose GM-CSF (150 microg/day on days 5-14)
Study: 285045
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy regimen A
Study: 285045
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy regimen B
Study: 31312931
Drug: Oral uracil-tegafur
Normalized name: tegafur / uracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral uracil-tegafur (UFT)
Study: 1907566
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate (100-200 mg daily)
Study: 6136346
Drug: Purified allergen
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified allergen preparation from Timothy pollen (Timothy N)
Study: 27807040
Drug: Combined intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intervention of albendazole (single dose), zinc (14 days), and daily multiple micronutrient powder for 24 weeks
Study: 22928615
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied on the right side of jaws (GaAlAs LLLT, 670 nm, 5 mW, 14 min/day for five consecutive days)
Study: 16162784
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL of 4% lidocaine (160 mg)
Study: 16162784
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL of saline solution as placebo
Study: 16162784
Drug: Combined sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sedation with 5 mg of IV hydrocodone and midazolam
Study: 14550328
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (home-based early intervention with weekly visits for 6 months and biweekly visits from 6 to 18 months)
Study: 9378845
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (day 2)
Study: 9378845
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch followed by nicotine gum (day 3)
Study: 9378845
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch followed by nicotine gum and cigarette smoking (day 4)
Study: 3946752
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (clindamycin and gentamicin)
Study: 30165984
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluticasone furoate and vilanterol
Study: 30165984
Drug: Highest quintile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quintile of cardiac troponin (≥7.7 ng/l)
Study: 20620737
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg load, then 90 mg twice daily; n=57)
Study: 20620737
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg load, then 75 mg daily; n=54)
Study: 19166421
Drug: Metronidazole-containing therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole-containing therapy (lansoprazole 15 mg once-daily, amoxicillin 500 mg twice-daily, metronidazole 250 mg twice-daily)
Study: 19166421
Drug: Clarithromycin-containing therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin-containing therapy (lansoprazole 15 mg once-daily, amoxicillin 500 mg twice-daily, clarithromycin 250 mg once-daily)
Study: 11833038
Drug: Transdermal 50
Normalized name: Banamine Transdermal 50 MG/ML Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 50 microg/d estradiol for 12 weeks (estrogen replacement therapy [ERT])
Study: 11833038
Drug: Transdermal 50
Normalized name: Banamine Transdermal 50 MG/ML Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 50 microg/d estradiol for 12 weeks (ERT)
Study: 10028105
Drug: Episodic or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Episodic or suppressive treatment
Study: 10028105
Drug: Type-specific serological
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type-specific serological tests for HSV antibodies
Study: 1672878
Drug: Levocabastine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine (0.5 mg/ml), nasal spray, twice in each nostril, four times a day
Study: 28922068
Drug: Flaxseed lignan-enriched
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed lignan-enriched complex (600 mg SDG)
Study: 23340005
Drug: Low-dose itraconazole
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose itraconazole (200 mg/day)
Study: 23340005
Drug: High-dose itraconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose itraconazole (600 mg/day)
Study: 17348989
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg/day for 12 months
Study: 15096079
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment with 2 mg of risperidone plus 2 mg of lorazepam
Study: 15096079
Drug: Intramuscular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular treatment with 5 mg of haloperidol plus 2 mg of lorazepam
Study: 9835726
Drug: Intramuscular route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular route for postoperative analgesia (POA)
Study: 2924690
Drug: Diuretic combination
Normalized name: atenolol and other diuretics, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic combination (hydrochlorothiazide + triamterene)
Study: 29630702
Drug: Bupropion hydrochloride,
Normalized name: BuPROPion Hydrochloride, 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion hydrochloride, 150 mg twice daily
Study: 29630702
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy, 21‐mg/d patch with tapering
Study: 27655905
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (6 courses of modified infusional fluorouracil and folinic acid with oxaliplatin before and after surgery)
Study: 27655905
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (modified infusional fluorouracil and folinic acid with oxaliplatin; 12 cycles)
Study: 16905398
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy with family unit including the patient